Bio-Techne Corporation(TECH)Earnings, Financials & Key Ratios

TECH•NASDAQ

$47.41

$7.42B mkt cap·103.1× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryLife Science Tools and Reagents

AboutBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.Show more

Revenue$1.22B+5.2%
EBITDA$212M-33.4%
Net Income$73M-56.3%
EPS (Diluted)0.46-56.2%
Gross Margin64.8%-2.4%
EBITDA Margin17.4%-36.7%
Operating Margin8.38%-53.0%
Net Margin6.02%-58.5%
ROE3.68%-55.8%
ROIC3.38%-50.1%
Debt/Equity0.23+14.1%
Interest Coverage12.57-1.8%

Technical→

TECH Key Insights

Bio-Techne Corporation (TECH) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓FCF machine: 21.0% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 10.5%
✓Healthy 5Y average net margin of 17.1%

✗Weaknesses

✗Profits declining 20.4% over 5 years
✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

TECH Price & Volume

Bio-Techne Corporation (TECH) stock price & volume — 10-year historical chart

Loading chart...

TECH Growth Metrics

Bio-Techne Corporation (TECH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years10.43%

5 Years10.55%

3 Years3.33%

TTM0.17%

Profit CAGR

10 Years-3.76%

5 Years-20.37%

3 Years-35.38%

TTM-16.79%

EPS CAGR

10 Years-4.38%

5 Years-20.52%

3 Years-34.8%

TTM-15.85%

Return on Capital

10 Years10.05%

5 Years10.21%

3 Years8.42%

Last Year4.15%

TECH Recent Earnings

Bio-Techne Corporation (TECH) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (25%)

Q2 2026Latest

May 6, 2026

EPS

$0.53

Est $0.55

-3.6%

Revenue

$311M

Est $316M

-1.5%

Q1 2026

Feb 4, 2026

EPS

$0.46

Est $0.43

+7.0%

Revenue

$296M

Est $290M

+1.9%

Q4 2025

Nov 5, 2025

EPS

$0.42

Est $0.42

-0.3%

Revenue

$287M

Est $291M

-1.6%

Q3 2025

Aug 6, 2025

EPS

$0.53

Est $0.50

+6.1%

Revenue

$317M

Est $295M

+7.6%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 6, 2026	$0.53vs $0.55-3.6%	$311Mvs $316M-1.5%
Q1 2026	Feb 4, 2026	$0.46vs $0.43+7.0%	$296Mvs $290M+1.9%
Q4 2025	Nov 5, 2025	$0.42vs $0.42-0.3%	$287Mvs $291M-1.6%
Q3 2025	Aug 6, 2025	$0.53vs $0.50+6.1%	$317Mvs $295M+7.6%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
RGENRepligen CorporationDirect Competitor	7.09B	125.76	146.23	16.36%	6.73%	2.46%	0.33
NEOGNeogen CorporationDirect Competitor	2B	9.18	-1.83	-3.2%	-68.47%	-28.64%	0.44
AZTAAzenta, Inc.Direct Competitor	846.61M	18.38	-15.07	3.55%	-29.86%	-10.69%	0.06
RVTYRevvity, Inc.Direct Competitor	11.08B	99.09	47.64	3.67%	8.3%	3.28%	0.48
MESOMesoblast LimitedDirect Competitor	2.04B	15.81	-18.82	191.39%	-5.94%	-17.1%	0.21
TMOThermo Fisher Scientific Inc.Product Competitor	175.76B	472.95	26.66	3.91%	15.18%	13.23%	0.76
DHRDanaher CorporationProduct Competitor	123.8B	174.92	34.71	2.9%	14.89%	7.06%	0.35
ILMNIllumina, Inc.Product Competitor	21.66B	142.58	26.16	-0.78%	19.43%	32.84%	0.94

Compare TECH vs Peers

Bio-Techne Corporation (TECH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RGEN

Most directly comparable listed peer for TECH.

Scale Benchmark

vs TMO

Larger-name benchmark to compare TECH against a more recognizable public peer.

Peer Set

Compare Top 5

vs RGEN, NEOG, AZTA, RVTY

TECH Income Statement

Bio-Techne Corporation (TECH) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Jun'17	Jun'18	Jun'19	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	Jun'25	TTM
Sales/Revenue	563M	642.99M	714.01M	738.69M	931.03M	1.11B	1.14B	1.16B	1.22B	1.21B
Revenue Growth %	12.82%	14.21%	11.04%	3.46%	26.04%	18.75%	2.81%	1.97%	5.23%	0.17%
Cost of Goods Sold	188.46M	210.85M	240.51M	255.5M	298.18M	349.1M	366.89M	389.33M	429.36M	424.32M
COGS % of Revenue	33.47%	32.79%	33.69%	34.59%	32.03%	31.58%	32.28%	33.59%	35.2%	-
Gross Profit	374.54M▲ 0%	432.14M▲ 15.4%	473.49M▲ 9.6%	483.19M▲ 2.0%	632.85M▲ 31.0%	756.5M▲ 19.5%	769.82M▲ 1.8%	769.73M▼ 0.0%	790.27M▲ 2.7%	786.49M▲ 0%
Gross Margin %	66.53%	67.21%	66.31%	65.41%	67.97%	68.42%	67.72%	66.41%	64.8%	64.96%
Gross Profit Growth %	11.25%	15.38%	9.57%	2.05%	30.97%	19.54%	1.76%	-0.01%	2.67%	-
Operating Expenses	252.76M	295.96M	326.77M	325.77M	395.55M	459.91M	470.87M	563.04M	688.02M	632.74M
OpEx % of Revenue	44.89%	46.03%	45.77%	44.1%	42.49%	41.6%	41.42%	48.58%	56.41%	-
Selling, General & Admin	199.24M	240.64M	264.36M	240.88M	289.92M	339M	352.44M	393.32M	415.1M	362.46M
SG&A % of Revenue	35.39%	37.42%	37.02%	32.61%	31.14%	30.66%	31.01%	33.93%	34.03%	-
Research & Development	53.51M	55.33M	62.41M	65.19M	70.6M	87.14M	92.49M	96.66M	99.5M	96.85M
R&D % of Revenue	9.51%	8.6%	8.74%	8.83%	7.58%	7.88%	8.14%	8.34%	8.16%	-
Other Operating Expenses	0	0	0	19.7M	35.03M	33.77M	25.94M	73.06M	173.42M	1000K
Operating Income	121.78M▲ 0%	136.18M▲ 11.8%	125.58M▼ 7.8%	157.42M▲ 25.4%	237.3M▲ 50.7%	296.59M▲ 25.0%	298.94M▲ 0.8%	206.69M▼ 30.9%	102.25M▼ 50.5%	153.75M▲ 0%
Operating Margin %	21.63%	21.18%	17.59%	21.31%	25.49%	26.83%	26.3%	17.83%	8.38%	12.7%
Operating Income Growth %	-19.13%	11.82%	-7.78%	25.35%	50.74%	24.99%	0.79%	-30.86%	-50.53%	-
EBITDA	181.82M	200.64M	203.75M	240.16M	325.04M	397.66M	406.18M	318.4M	212.16M	180.87M
EBITDA Margin %	32.29%	31.2%	28.54%	32.51%	34.91%	35.97%	35.73%	27.47%	17.4%	14.94%
EBITDA Growth %	-5.97%	10.35%	1.55%	17.87%	35.35%	22.34%	2.14%	-21.61%	-33.37%	-36.04%
D&A (Non-Cash Add-back)	60.04M	64.46M	78.17M	82.74M	87.75M	101.07M	107.24M	111.71M	109.9M	27.11M
EBIT	119.32M	136.14M	133.72M	295.67M	162.13M	312.69M	349.87M	201.43M	106.97M	83.2M
Net Interest Income	-7.06M	-9.78M	-21.14M	-18.59M	-13.48M	-10.52M	-7.8M	-12.41M	-4.62M	-4.83M
Interest Income	304K	409K	569K	605K	473K	794K	3.41M	3.32M	3.89M	585K
Interest Expense	7.36M	10.19M	21.7M	19.2M	13.95M	11.31M	11.21M	15.74M	8.51M	2.18M
Other Income/Expense	-8.62M	-10.23M	-34.7M	119.06M	-89.12M	4.8M	39.72M	-21M	-3.79M	-6.61M
Pretax Income	113.16M▲ 0%	125.95M▲ 11.3%	112.02M▼ 11.1%	276.48M▲ 146.8%	148.18M▼ 46.4%	301.39M▲ 103.4%	338.66M▲ 12.4%	185.69M▼ 45.2%	98.46M▼ 47.0%	147.14M▲ 0%
Pretax Margin %	20.1%	19.59%	15.69%	37.43%	15.92%	27.26%	29.79%	16.02%	8.07%	12.15%
Income Tax	35.88M	-602K	15.94M	47.18M	8.59M	38.29M	53.22M	17.58M	25.06M	37.58M
Effective Tax Rate %	31.7%	-0.48%	14.23%	17.07%	5.8%	12.7%	15.71%	9.47%	25.45%	25.54%
Net Income	77.29M▲ 0%	125.35M▲ 62.2%	96.07M▼ 23.4%	229.3M▲ 138.7%	140.41M▼ 38.8%	272.05M▲ 93.8%	285.26M▲ 4.9%	168.1M▼ 41.1%	73.4M▼ 56.3%	109.56M▲ 0%
Net Margin %	13.73%	19.49%	13.46%	31.04%	15.08%	24.61%	25.1%	14.5%	6.02%	9.05%
Net Income Growth %	-26.03%	62.19%	-23.36%	138.67%	-38.76%	93.75%	4.86%	-41.07%	-56.34%	-16.79%
Net Income (Continuing)	76.09M	126.15M	96.07M	229.3M	139.59M	263.1M	285.44M	168.1M	73.4M	58.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	8.26M	-759K	0	0	0	0
EPS (Diluted)	0.52▲ 0%	0.82▲ 57.7%	0.62▼ 24.4%	1.45▲ 133.9%	0.87▼ 40.0%	1.66▲ 90.8%	1.76▲ 6.0%	1.05▼ 40.3%	0.46▼ 56.2%	0.70▲ 0%
EPS Growth %	-25.71%	57.69%	-24.39%	133.87%	-40%	90.8%	6.02%	-40.34%	-56.19%	-15.85%
EPS (Basic)	0.52	0.84	0.64	1.50	0.91	1.73	1.81	1.07	0.47	-
Diluted Shares Outstanding	150M	152.22M	155.57M	157.6M	161.93M	164.12M	161.85M	160.77M	159.72M	156.94M
Basic Shares Outstanding	149.25M	149.9M	151.12M	152.8M	154.99M	156.88M	157.18M	157.71M	157.52M	155.89M
Dividend Payout Ratio	61.23%	38.27%	50.34%	21.33%	35.34%	18.45%	17.63%	29.99%	68.65%	-

TECH Balance Sheet

Bio-Techne Corporation (TECH) balance sheet — assets, liabilities & shareholders' equity

Line item	Jun'17	Jun'18	Jun'19	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	Jun'25	TTM
Total Current Assets	345.26M	398.37M	412.61M	520.92M	510.61M	605.56M	621.48M	617.42M	608.3M	688.05M
Cash & Short-Term Investments	157.71M	181.75M	166.03M	270.89M	231.55M	247.03M	204.31M	152.86M	162.19M	209.82M
Cash Only	91.61M	121.99M	100.89M	146.63M	199.09M	172.57M	180.57M	151.79M	162.19M	209.82M
Short-Term Investments	66.1M	59.76M	65.15M	124.27M	32.46M	74.46M	23.74M	1.07M	0	0
Accounts Receivable	116.83M	120.3M	137.47M	122.53M	145.38M	194.55M	218.47M	241.39M	206.88M	214.56M
Days Sales Outstanding	75.74	68.29	70.27	60.55	57	64.23	70.15	76.02	61.91	59.53
Inventory	60.15M	85.65M	91.05M	103.15M	116.75M	141.12M	171.64M	179.73M	189.45M	201.18M
Days Inventory Outstanding	116.5	148.26	138.18	147.36	142.91	147.55	170.76	168.5	161.05	171.88
Other Current Assets	13.33M	10.67M	18.06M	24.34M	16.92M	22.86M	27.07M	43.43M	49.79M	62.49M
Total Non-Current Assets	1.21B	1.19B	1.47B	1.51B	1.75B	1.69B	2.02B	2.09B	1.95B	1.86B
Property, Plant & Equipment	135.12M	145.35M	154.04M	248.29M	281.74M	288.8M	324.53M	342.44M	319.12M	301.31M
Fixed Asset Turnover	4.17x	4.42x	4.64x	2.98x	3.30x	3.83x	3.50x	3.38x	3.82x	3.92x
Goodwill	579.03M	597.89M	732.67M	728.31M	843.07M	822.1M	872.74M	972.66M	980.93M	977.8M
Intangible Assets	452.04M	446.33M	579.43M	516.54M	615.97M	531.52M	534.64M	507.08M	365.6M	319.07M
Long-Term Investments	40.38M	2.66M	-89.75M	0	0	0	255.86M	242.34M	250.98M	767.37M
Other Non-Current Assets	-116.98M	-83.69M	5.67M	13.52M	11.3M	46.83M	29.45M	21.93M	22.63M	314.26M
Total Assets	1.56B▲ 0%	1.59B▲ 2.3%	1.88B▲ 18.3%	2.03B▲ 7.6%	2.26B▲ 11.6%	2.29B▲ 1.4%	2.64B▲ 15.0%	2.7B▲ 2.5%	2.56B▼ 5.4%	2.55B▲ 0%
Asset Turnover	0.36x	0.40x	0.38x	0.36x	0.41x	0.48x	0.43x	0.43x	0.48x	0.48x
Asset Growth %	37.82%	2.35%	18.28%	7.6%	11.61%	1.41%	14.99%	2.47%	-5.4%	-22.14%
Total Current Liabilities	135.36M	78.69M	101.98M	106.67M	152.28M	176.02M	128.51M	159.38M	175.85M	153.28M
Accounts Payable	16.86M	18.45M	16.21M	23.09M	29.38M	33.87M	25.68M	37.97M	25.31M	0
Days Payables Outstanding	32.65	31.94	24.6	32.99	35.97	35.41	25.55	35.59	21.52	17.58
Short-Term Debt	0	0	12.5M	12.5M	12.5M	12.5M	0	0	0	0
Deferred Revenue (Current)	5.97M	7.07M	9.08M	13.05M	19M	23.41M	23.07M	27.93M	32.57M	94.05M
Other Current Liabilities	65.1M	21.4M	3.4M	0	3.89M	1.24M	1.41M	2.15M	1.65M	153.28M
Current Ratio	2.55x	5.06x	4.05x	4.88x	3.35x	3.44x	4.84x	3.87x	3.46x	3.46x
Quick Ratio	2.11x	3.97x	3.15x	3.92x	2.59x	2.64x	3.50x	2.75x	2.38x	2.38x
Cash Conversion Cycle	159.59	184.61	183.85	174.92	163.94	176.37	215.36	208.92	201.44	213.83
Total Non-Current Liabilities	470.47M	435.37M	616.84M	539.73M	539.44M	417.78M	543.67M	475.64M	463.21M	290.35M
Long-Term Debt	343.77M	339M	492.66M	344.24M	328.83M	243.41M	350M	319M	346M	276.14M
Capital Lease Obligations	0	0	0	67.25M	67.63M	58.13M	93.77M	87.62M	83.96M	241.85M
Deferred Tax Liabilities	118M	86.29M	89.75M	101.09M	93.13M	98.99M	88.98M	55.86M	6.17M	42.67M
Other Non-Current Liabilities	129.3M	9.34M	33.11M	27.15M	49.86M	17.24M	10.92M	13.16M	27.08M	93.39M
Total Liabilities	605.83M	514.06M	718.82M	646.4M	691.72M	593.79M	672.18M	635.02M	639.06M	443.63M
Total Debt	349.9M	339M	505.16M	433.53M	420.55M	325.97M	454.96M	419.54M	444.06M	276.14M
Net Debt	258.29M	217.01M	404.27M	286.9M	221.46M	153.4M	274.39M	267.75M	281.87M	66.32M
Debt / Equity	0.37x	0.31x	0.43x	0.31x	0.27x	0.19x	0.23x	0.20x	0.23x	0.23x
Debt / EBITDA	1.92x	1.69x	2.48x	1.81x	1.29x	0.82x	1.12x	1.32x	2.09x	1.53x
Net Debt / EBITDA	1.42x	1.08x	1.98x	1.19x	0.68x	0.39x	0.68x	0.84x	1.33x	1.33x
Interest Coverage	16.21x	13.36x	6.16x	15.40x	11.62x	27.65x	31.20x	12.80x	12.57x	38.20x
Total Equity	950.83M▲ 0%	1.08B▲ 13.5%	1.17B▲ 8.0%	1.38B▲ 18.5%	1.57B▲ 13.8%	1.7B▲ 8.3%	1.97B▲ 15.6%	2.07B▲ 5.2%	1.92B▼ 7.3%	2.11B▲ 0%
Equity Growth %	8.14%	13.5%	8.01%	18.5%	13.76%	8.26%	15.61%	5.2%	-7.25%	-14.17%
Book Value per Share	6.34	7.09	7.49	8.76	9.70	10.36	12.15	12.87	12.01	13.43
Total Shareholders' Equity	950.83M	1.08B	1.17B	1.38B	1.56B	1.7B	1.97B	2.07B	1.92B	2.11B
Common Stock	374K	376K	379K	385K	390K	1.57M	1.58M	1.58M	1.55M	1.56M
Retained Earnings	799.03M	876.93M	931.93M	1.06B	1.09B	1.12B	1.31B	1.33B	1.07B	1.15B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-48.94M	-44.81M	-83.52M	-97.2M	-57.29M	-75.2M	-66.06M	-78.32M	-59.88M	-66.86M
Minority Interest	0	0	0	0	8.26M	-759K	0	0	0	0

TECH Cash Flow Statement

Bio-Techne Corporation (TECH) cash flow — operating, investing & free cash flow history

Line item	Jun'17	Jun'18	Jun'19	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	Jun'25	TTM
Cash from Operations	143.45M	170.37M	181.62M	205.22M	352.16M	325.27M	254.39M	298.98M	287.56M	287.56M
Operating CF Margin %	25.48%	26.5%	25.44%	27.78%	37.83%	29.42%	22.38%	25.8%	23.58%	-
Operating CF Growth %	-0.29%	18.77%	6.6%	12.99%	71.61%	-7.64%	-21.79%	17.53%	-3.82%	81.71%
Net Income	76.09M	126.15M	96.07M	229.3M	139.59M	263.1M	285.44M	168.07M	73.4M	109.56M
Depreciation & Amortization	60.04M	64.46M	78.17M	82.74M	87.75M	101.07M	107.24M	111.71M	109.9M	100.33M
Stock-Based Compensation	14.63M	28.24M	32.28M	32.37M	48.98M	42.18M	39.23M	38.04M	40.83M	40.69M
Deferred Taxes	-3.43M	-46.72M	-13.58M	13.13M	-27.43M	6.82M	-29.57M	-39.45M	-51.11M	-24.24M
Other Non-Cash Items	10.06M	-3.67M	16.43M	-147.07M	74.02M	-18.38M	-57.37M	30.71M	102.99M	46.95M
Working Capital Changes	-13.93M	1.9M	-27.75M	-5.25M	29.26M	-69.52M	-90.58M	-10.11M	11.54M	21.57M
Change in Receivables	-19.69M	-308.66M	-2.7M	6.56M	-15.55M	-57.6M	-23.36M	-31.13M	42.6M	45.24M
Change in Inventory	-732K	-13.33M	-13.65M	-14.86M	-7.14M	-32.01M	-30.17M	-14.21M	-18.14M	-6.6M
Change in Payables	5.7M	5.03M	6.1M	10.34M	19.09M	12.74M	-7.91M	25.77M	-13.95M	-13.31M
Cash from Investing	-305.95M	-38.71M	-336.8M	27.09M	-243.52M	-96.85M	-265.65M	-203.03M	-35.18M	-10.73M
Capital Expenditures	-15.18M	-20.93M	-25.41M	-51.74M	-44.3M	-44.91M	-38.24M	-62.88M	-31.01M	-25.26M
CapEx % of Revenue	2.7%	3.26%	3.56%	7%	4.76%	4.06%	3.36%	5.42%	2.54%	-
Acquisitions	-293.79M	-46.28M	-289.49M	1.91M	-225.91M	0	-83.36M	-169.71M	-15M	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-36.99M	680K	-21.9M	0	0	-53M	-232M	7M	15.26M	14.53M
Cash from Financing	189.39M	-99.19M	134.38M	-183.8M	-62.55M	-242.85M	22.62M	-122.4M	-253.91M	-226.36M
Debt Issued (Net)	252M	-4.5M	166.5M	-148.5M	-15.5M	-85.5M	94M	-31M	27M	-30M
Equity Issued (Net)	0	0	-15.4M	-50.11M	-43.18M	-160.95M	-19.56M	-80.04M	-275.73M	-100.11M
Dividends Paid	-47.33M	-47.97M	-48.36M	-48.9M	-49.62M	-50.19M	-50.28M	-50.42M	-50.39M	-49.82M
Share Repurchases	0	0	-15.4M	-50.11M	-43.18M	-160.95M	-19.56M	-80.04M	-275.73M	-100.08M
Other Financing	-15.56M	-46.72M	31.65M	63.71M	45.75M	53.78M	-1.54M	39.06M	45.22M	-46.43M
Net Change in Cash	27.38M▲ 0%	30.38M▲ 11.0%	-21.1M▼ 169.5%	45.74M▲ 316.7%	52.47M▲ 14.7%	-26.52M▼ 150.6%	8M▲ 130.2%	-28.78M▼ 459.6%	10.39M▲ 136.1%	69.15M▲ 0%
Free Cash Flow	128.27M▲ 0%	149.43M▲ 16.5%	156.21M▲ 4.5%	153.47M▼ 1.8%	307.86M▲ 100.6%	280.36M▼ 8.9%	216.15M▼ 22.9%	236.1M▲ 9.2%	256.55M▲ 8.7%	269.6M▲ 0%
FCF Margin %	22.78%	23.24%	21.88%	20.78%	33.07%	25.36%	19.02%	20.37%	21.04%	22.27%
FCF Growth %	1.02%	16.5%	4.53%	-1.75%	100.6%	-8.93%	-22.9%	9.23%	8.66%	22.13%
FCF per Share	0.86	0.98	1.00	0.97	1.90	1.71	1.34	1.47	1.61	1.61
FCF Conversion (FCF/Net Income)	1.86x	1.36x	1.89x	0.89x	2.51x	1.20x	0.89x	1.78x	3.92x	2.46x
Interest Paid	7.45M	9.84M	21.5M	18.61M	13.58M	11.03M	8.37M	14.5M	18.95M	9.54M
Taxes Paid	42.9M	35.08M	36.81M	41.99M	20.95M	30.34M	88.43M	65.25M	74.36M	-9.41M

TECH Key Ratios

Bio-Techne Corporation (TECH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	8.45%	12.35%	8.56%	18.01%	9.51%	16.63%	15.56%	8.33%	3.68%	5.48%
Return on Invested Capital (ROIC)	8.47%	8.15%	6.57%	7.29%	10.29%	12.2%	10.95%	6.77%	3.38%	3.38%
Gross Margin	66.53%	67.21%	66.31%	65.41%	67.97%	68.42%	67.72%	66.41%	64.8%	64.96%
Net Margin	13.73%	19.49%	13.46%	31.04%	15.08%	24.61%	25.1%	14.5%	6.02%	9.05%
Debt / Equity	0.37x	0.31x	0.43x	0.31x	0.27x	0.19x	0.23x	0.20x	0.23x	0.23x
Interest Coverage	16.21x	13.36x	6.16x	15.40x	11.62x	27.65x	31.20x	12.80x	12.57x	38.20x
FCF Conversion	1.86x	1.36x	1.89x	0.89x	2.51x	1.20x	0.89x	1.78x	3.92x	2.46x
Revenue Growth	12.82%	14.21%	11.04%	3.46%	26.04%	18.75%	2.81%	1.97%	5.23%	0.17%

TECH SEC Filings & Documents

Bio-Techne Corporation (TECH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 6, 2026·SEC

Material company update

Feb 11, 2026·SEC

Material company update

Feb 4, 2026·SEC

10-K Annual Reports

FY 2025

Aug 22, 2025·SEC

FY 2024

Aug 22, 2024·SEC

FY 2023

Aug 23, 2023·SEC

10-Q Quarterly Reports

FY 2026

May 6, 2026·SEC

FY 2026

Feb 4, 2026·SEC

FY 2025

Nov 5, 2025·SEC

TECH Frequently Asked Questions

Bio-Techne Corporation (TECH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Bio-Techne Corporation (TECH) reported $1.21B in revenue for fiscal year 2025. This represents a 2118% increase from $54.6M in 1996.

Bio-Techne Corporation (TECH) grew revenue by 5.2% over the past year. This is steady growth.

Yes, Bio-Techne Corporation (TECH) is profitable, generating $109.6M in net income for fiscal year 2025 (6.0% net margin).

Dividend & Returns

Yes, Bio-Techne Corporation (TECH) pays a dividend with a yield of 0.67%. This makes it attractive for income-focused investors.

Bio-Techne Corporation (TECH) has a return on equity (ROE) of 3.7%. This is below average, suggesting room for improvement.

Bio-Techne Corporation (TECH) generated $269.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More TECH

Bio-Techne Corporation (TECH) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Bio-Techne Corporation(TECH)Earnings, Financials & Key Ratios

TECH Key Insights

✓Strengths

✗Weaknesses

TECH Price & Volume

TECH Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

TECH Recent Earnings

TECH Peer Comparison

Compare TECH vs Peers

vs RGEN

vs TMO

Compare Top 5

TECH Income Statement

TECH Balance Sheet

TECH Cash Flow Statement

TECH Key Ratios

TECH SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

TECH Frequently Asked Questions

Explore More TECH

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation